Biopharmaceutical Development: Innovations Impacting Development
BioPharm International® spoke with Oury Chetboun, CEO of Seekyo Therapeutics, to get his perspective on what impact new modalities and technology innovations are having on biopharmaceutical development.
The biopharma industry is seeing growth in innovation with new treatments for cancer and autoimmune diseases and the development of specialized medicines. New technologies, such as artificial intelligence and machine learning, are also having an impact on drug development and manufacturing.
New drugs come with the cost to develop and produce before they can reach patients. According to Oury Chetboun, CEO of Seekyo Therapeutics, one trend that is advancing the biopharma industry is continuous manufacturing, which can reduce time to market. “You may have a fantastic drug [in the lab] which costs [a] massive [amount] to be scaled up, but if you can't get that into a large-scale production or at a reasonable cost, then you can't do anything,” Chetboun cautions.
Click the video above to watch the full interview.
About the speaker
Oury Chetboun is CEO of Seekyo Therapeutics. He has a background in immunology and has been working in business development for 20 years. Seekyo develops solid cancer treatments that target functional proteins.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
Mechanistic Hypothesis of Toxicity: Driving Decision Making in Preclinical Translation
July 16th 2025Mechanistic toxicity hypothesis is essential in guiding decision-making and predicting toxicities during the preclinical stages of drug development. The authors highlight the growing importance of integrating advanced technologies like mass spectrometry imaging into toxicology to enhance preclinical translation, foster innovation in therapeutic development, and ultimately improve drug safety and efficacy.
